Introduction
Cardiac fibrosis and cardiomyocyte hypertrophy are two key pathologic features that occur secondary to hypertensive heart disease.
1,2 Cardiac fibrosis is a major cause of cardiac insufficiency and contributes to both systolic and diastolic dysfunction. 3 Therefore, a better understanding of the process of cardiac fibrosis may contribute to the development of novel strategies for therapeutic intervention. Activated cardiac myofibroblasts (CMFs) are the main cell type responsible for increased interstitial collagen accumulation in fibrotic cardiac remodelling. 4, 5 CMFs directly secrete collagens, matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs), thus regulating extracellular matrix turnover and homeostasis. 6 In response to cardiac injury, CMFs are activated, their proliferative and migratory responses increase and collagen biosynthesis is favoured. Although increased collagen synthesis can tentatively stabilize cardiac function in response to cardiac injury, excessive disorganization of the collagen network will reduce the elasticity of the myocardium, eventually resulting in the development of heart failure. 6, 7 In 2008, it was found that OGN expression is increased in the myocardium in patients with hypertensive heart disease compared to control patients. 8 However, its exact role and means of regulation during cardiac hypertrophy are not fully elucidated. Besides, the role of OGN in the process of fibrosis is especially confusing and complicated. On one hand, loss of OGN led to less and inadequate fibrosis following ischemic heart failure, 9 whereas down-regulation of OGN in aging hearts facilitated migration of cardiac fibroblasts, promoting aging associated cardiac fibrosis. 10 Since myocardial infarction is an acute injury, how OGN works in response to chronic injury such as hypertension-associated cardiac fibrosis remain to be uncovered.
In the present study, we sought to test the hypothesis that OGN is an important modulator of cardiac fibrosis. To examine this, we used OGN-deficient mice to observe cardiac remodelling and function in angiotensin II (Ang II) infused models. We observed a significant increase of fibrosis and enhanced proliferative activity in OGN deficient mice after Ang II stimuli, without any change in blood pressure, cell apoptosis or fibroblast differentiation.
Methods
See Supplementary material online for detailed Methods section.
Animals
All animal procedures performed conform the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes; and all the procedures were approved by the Animal Care Committee of Shanghai Jiaotong University and in compliance with the animal management rules of the Chinese Ministry of Health and NIH guidelines. Generation of osteoglycin-null mice (OGN -/-) mice has been described in detail before. 9, 11 They were backcrossed to C57Bl/6 J for more than 15 generations. The OGN -/-mice and wild-type (WT) control littermates (OGN þ/þ ) were maintained on a 14-h light, 10-h dark schedule with access to rodent lab chow and water.
Ang II-induced hypertension model
Hypertensive cardiac remodelling was induced in genetically identical littermates of OGN null mice (OGN -/-) mic and WT mice by subcutaneous infusion of Ang II at a dose of 1000 ng/kg/min for 14 days via osmotic mini-pumps (model 2002; Alza Corp.). Mice were anesthetized with 1.5% isoflurane inhalation. Pumps were implanted subcutaneously according to the manufacturers' instructions. Pumps were infused with saline in the control groups.
Ki16425 treatment group, after implantation of mini-pumps infused with Ang II or saline, Ki16425 (20 mg/kg body weight, dissolved in 5% DMSO/corn oil) was intraperitoneally injected once per day for 2 weeks.
Statistical analysis
Data analysis was performed using GraphPad Prism software (version 6.0). All data were presented as the mean ± SEM. Comparison between two groups were analyzed by Student's t test or two-way analysis of variance with Bonferroni's multiple comparison post hoc tests. P-values less than 0.05 were considered statistically significant.
Results

OGN deficient mice exhibit enhanced cardiac fibrosis and impaired cardiac function following chronic Ang II infusion
Previous studies showed that OGN expression is increased in the infarcted left ventricle of mice and in the hearts of patients with ischemic heart disease. 9 Here, we examined the effect of Ang II infusion on OGN expression. Protein levels of OGN were strikingly elevated in a timedependent manner during a 2-week infusion of Ang II, reaching levels four-to six-fold higher at 14 d compared with baseline ( Figure 1A ). To investigate whether OGN regulates hypertensive cardiac remodelling, we used both male and female OGN deficient (OGN -/-) mice to observe changes in the heart following infusion of Ang II. Homozygous OGN -/-mice and control WT mice were genotyped and evaluated by western blot and real time PCR (Supplementary material online, Figure  S1 ). No significant changes of cardiac size and weight were present in OGN deficient mice at baseline, but the increase in cardiac size and weight following 2-weeks of Ang II infusion was significantly augmented in the OGN -/-mice compared to WT (8.91 ± 0.18 vs. WT 8.15 ± 0.23; P < 0.05; Figure 1B and C). Of note, the increase in blood pressure and cardiomyocyte cross-sectional area did not differ between OGN -/-mice and WT control littermates ( Figure 1D and F, and Supplementary material online, Figure S2A ), suggesting that OGN does not influence cardiomyocyte hypertrophy, and the difference of cardiac remodelling between the two genotypes are blood pressure independent. Importantly, we detected a marked increase of collagen I in OGN -/-hearts following infusion of Ang II (Supplementary material online, Figure  S2B and C). Masson's trichrome staining and picrosirius red staining further demonstrated enhanced ventricular fibrosis in OGN -/-mice compared to WT control littermates ( Figure 1G and H). There is no significant difference between the male and female groups in terms of blood pressure or the prevalence of cardiac hypertrophy and cardiac fibrosis ( Figure 1C -H, Supplementary material online, Figure S2B and C). However, polarized light microscopy of sirius red-stained sections showed that the ratio of insoluble to soluble collagen was higher in normotensive WT mice, whereas no difference was found between the genotypes following Ang II infusion. Besides, in collagen plug formation analysis, when collagen was incubated with OGN, the polymerization of collagen fibers was significantly enhanced (Supplementary material online, Figure S3A and B, and Table S1 ), suggesting that OGN could promote the cross-linking of collagen fiber. In addition, transmission electron at 2 weeks after Ang II infusion. The ratio of heart weight to tibia length in male mice (C) and female mice (E). microscopy revealed that collagen fibers from OGN deficient hearts were disorganized with less uniform cross-sectional diameter (Supplementary material online, Figure S3C ). Echocardiographic assessment demonstrated impaired cardiac systolic and diastolic function in OGN -/-mice following infusion of Ang II (Table 1) . Besides, we observed a nearly 22% mortality in OGN -/-mice following 2 weeks of Ang II infusion due to the occurrence of aortic dissection related rupture, whereas no deaths occurred in the WT mice (Supplementary material online, Figure S3D ). Transverse aortic constriction (TAC), another classical pressure overloaded model, was performed, which also leads to intense cardiac fibrosis. Consistently, OGN deficient mice displayed significantly increased ventricular fibrosis (Supplementary material online, Figure S4 ).
Loss of OGN results in increased activation of MAPK signalling in hearts
Since a significant increase in collagen deposition was observed in the cardiac tissue of OGN -/-mice following infusion of Ang II, we next determine whether TGF-b1 signalling is altered in OGN -/-hearts.
TGF-b1 signalling is activated during cardiac remodelling and promotes excessive extracellular matrix protein accumulation. However, neither transforming growth factor-beta (TGF-b1) release nor phosphorylation of smad2/3 was altered by the deletion of OGN (Supplementary material online, Figure S5A and B). Next, we observed the effect of OGN deficiency on myofibroblast differentiation. Immunostaining for smooth muscle a-actin (SMA)-positive myofibroblasts and western blot analysis showed that there was no difference of differentiation efficiency between OGN -/-and WT CMFs (Supplementary material online, Figure S6 ). Figure S7D ) suggesting that OGN regulates proliferation activity. Mitogen-activated protein kinases (MAPKs) activation is involved in cardiac hypertrophy, regulating various cellular responses such as cell proliferation, migration and survival. 12, 13 We observed a significantly increased activation of extracellular signal-regulated MAP Kinases (ERK)1/2 in Ang II-treated OGN -/-hearts ( Figure 2B ).
OGN negatively regulates CMF proliferation and migration through EGFR pathway
Since proliferation activity and ERK1/2 activation were greatly increased in Ang II-treated OGN -/-hearts, and CMFs are the main cell type responsible for cardiac fibrosis and secrete much more OGN than cardiac Figure S8 ). However, loss of OGN notably enhanced the proliferation and migration of CMFs compared with WT CMFs when stimulated with Ang II ( Figure 3A and B) , indicating a regulatory role of OGN in CMF proliferation and mobility. Epidermal growth factor receptor (EGFR) phosphorylation activates multiple MAPKs including ERK1/2 and contributes to Ang II-stimulated cell proliferation and migration. 14 We detected a significantly enhanced phosphorylation of EGFR and ERK1/2 in Ang II-stimulated OGN -/-CMFs ( Figure 4A) . Moreover, the enhanced EGFR signalling, proliferation and migration in OGN -/-CMFs was markedly reduced by pretreatment with two specific EGFR inhibitors, Erlotinib and AG1478 ( Figure 4A-C) , further demonstrating that OGN regulates mitogenic and migratory cellular effects through EGFR dependent signalling. Similarly, OGN deficiency promoted EGFR and ERK1/2 phosphorylation in CMFs cultured from adult mice as it in CMFs cultured from neonate mice (Supplementary material online, Figure S9 ). In contrast, restoration of OGN in OGN -/-CMFs could decrease EGFR activation and inhibit the ability of CMF proliferation and migration (Supplementary material online, Figure S10 ).
OGN inhibits MMP-2 mediated ectodomain shedding of EGF-like ligands
EGF and EGF-like ligands such as heparin-binding EGF (HB-EGF), TGFa and amphiregulin are known to bind and activate EGFR, leading to phosphorylation of the EGFR and initiation of downstream MAPK activation. We therefore sought to determine whether Figure S11 ). Since EGFR ligands were synthesized as membrane anchored proteins and released on cleavage by proteases, 15 we hypothesized that OGN mediates the reduction of shedding, but not the synthesis of EGF-like ligands. Further, the enhanced HB-EGF and amphiregulin in culture media from OGN -/-CMFs was significantly suppressed by overexpression of OGN ( Figure 5A ). Membrane anchored proHB-EGF and proamphiregulin can be cleaved by matrix MMPs and a disintegrin and metalloproteases (ADAMs). 16, 17 We examined mRNA levels of the MMPs and ADAMs family and identified a significant increase of MMP-2 expression in OGN -/-CMFs (Supplementary material online, Figure S12 ). Furthermore, gelatin zymography assay showed increased MMP-2 activity in the culture of OGN Figure  S13A ). Next, we sought to determine whether the increased membrane translocation of MT1-MMP after OGN loss is regulated by RhoA/ ROCK-dependent actin polymerization. As assessed by rhodamine phalloidin staining, OGN -/-CMFs exhibited an increase in F-actin polymerization following Ang II stimulation (Supplementary material online, Figure  S13B and C), and this was inhibited by the addition of exogenous recombinant OGN core protein in a dose dependent manner, or suppressed by adenoviral overexpression of OGN (Supplementary material online, Figure S13D -G), suggesting that both endogenous and exogenous OGN similarly affect cytoskeleton remodelling. Furthermore, the augmented polymerization of F-actin in OGN -/-CMFs was decreased by pretreatment with the Rho inhibitor C3 transferase (C3), the ROCK inhibitor Y-27632, and the actin polymerization inhibitor latrunculin B (LB), correlating with decreased proliferation and migration (Supplementary material online, Figure S14 ). Taken together, these results indicate that OGN blunts Ang II-induced filamentous stress fiber formation and suppresses MT1-MMP movement in CMFs through Rho/ ROCK-dependent cytoskeletal remodelling.
3.6 OGN binds to LPA3 to block LPA mediated activation of Rho/ROCK/MMP-2/ EGFR signalling in CMFs stimulated with Ang II
Previous studies indicated that lysophosphatidic acid (LPA) is a potent Rho activator, and that it binds to G protein coupled LPA receptor subtypes (LPA1-6), leading to stress fiber formation and EKR phosphorylation. 19 On the basis of the reduced filamentous stress fiber formation observed in OGN-overexpressing CMFs, we hypothesized that OGN binds to the LPA receptor to block LPA-mediated cytoskeletal remodelling. Using specific LPA1/3 antagonist Ki16425 significantly retarded the filamentous fiber formation and reduced the phosphorylation of EGFR in OGN -/-CMFs (Supplementary material online, Figure   S15 ), suggesting OGN binds to either LPA1 or LPA3 to inhibit activation of EGFR signalling. To identify the exact LPA receptor to which OGN binds, siRNAs against LPA1 and LPA3 were transfected into WT and OGN -/-CMFs. Real-time PCR results showed that LPA1/3 mRNA expression was reduced by 75-80% in primary CMFs (Supplementary material online, Figure S16A ). Interestingly, knockdown of LPA3, but not LPA1, significantly suppressed F actin polymerization, associated with reduced CMFs mitogenicity and mobility (Supplementary material online, Figure S16B -E). To further confirm that extracellular OGN interacts with LPA3 to play its inhibitory role, flag-tagged OGN was introduced into OGN -/-CMFs, and co-immunoprecipitated using a flag-tag antibody. This experiment revealed LPA3, but not LPA1, in the flag-OGN immunocomplex (Supplementary material online, Figure S16F ).
To further confirm the close interaction between OGN and LPA3 in vivo, OGN -/-mice were treated with Ki16425 (20 mg/kg, once daily for 2 weeks) or control vehicles. The increased cardiac hypertrophy and enhanced cardiac interstitial fibrosis in OGN -/-mice were notably alleviated by treatment with Ki16425 ( Figure 6 ). Meanwhile, cardiac function was also improved (Supplementary material online, Table S2 ). Taken together, these data suggest that OGN binds to LPA3, suppressing Rho-dependent EGFR signalling in Ang II stimulated or pressure overloaded cardiac remodelling. (Figure 7 ).
Discussion
In this study, we found that OGN deficiency enhanced the increase of cardiac size following Ang II infusion, while the cardiomyocyte crosssectional area was not different. These results were inconsistent with the report from Petretto et al. that OGN deficiency seemed to reduce left ventricular mass (LVM) in mice. 8 It is likely that they only observed hypertrophy by LV mass without histological analysis of cardiac fibrosis and cardiomyocyte cross-sectional area. Moreover, OGN expression is affected by age and duration of Ang II infusion. Our results are consistent with the very recent publication that studied aged OGN null and WT mice infused with Ang II. 20 We also found that OGN regulates fibroblast proliferation and cardiac fibrosis in response to Ang II. Evidence suggests myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. Furthermore, cardiac fibroblasts participate in cardiac hypertrophy possibly through producing extracellular matrix and paracrine communications with cardiomyocytes. 22 Therefore, the higher incidence of cardiac hypertrophy in hypertensive OGN -/-mice is likely a consequence of increased cardiac fibrosis. Additionally, there is a slight reduction of EF and FS in the WT mice, while the decrease is more notable in the knockout mice. These results suggest that a possible compensatory cardiac response to Ang II is promoted in OGN knockout mice. It is reported that progressive myocardial fibrosis was strongly correlated with the systolic function decline. 23 Meanwhile, excessive myocardial fibrosis also deteriorates diastolic function in hearts. 24 By using magnetic resonance imaging, Deckx et al. showed that OGN prevents diastolic dysfunction during pressure overload by reducing cardiac fibrosis, 20 which is consistent with our finding that OGN deletion augmented diastolic dysfunction. Therefore, OGN regulates cardiac dysfunction possibly through cardiac fibroblast-mediated fibrosis.
Our results also suggest a protective role of OGN against hypertension associated cardiac fibrosis. First, we found that OGN expression is increased by Ang II infusion, while Jazbutyte et al. found that OGN is decreased in aging hearts. 10 Of note, Jazbutyte and colleagues used an aging model with no Ang II infusion, which may be the cause of the inconsistent conclusions. Furthermore, contrasting to some extent with previous myocardial infarction studies in collagen quantity and quality, we observed an increased quantity of collagen in OGN deficient mice following Ang II infusion, whereas that did not differ between genotypes in the model of myocardial infarction. Besides, both we and Deckx et al. observed no difference between genotypes in insoluble and soluble collagen ratio in hypertensive hearts, 20 whereas that was sharply decreased in infarcted hearts. This may be due to the differences in the pathophysiology of the models. Myocardial infarction is an acute process of collagen secretion and maturation, with profound replacement of the necrotic tissue, called reparative fibrosis. The Ang II infusion model is characterized by a chronic injury causing interstitial fibrosis, called reactive fibrosis., Similarly, in the TAC model, chronic pressure overload compromises ventricular function and contributes to congestive heart failure, also mainly resulting in reactive cardiac fibrosis. 25 TGF-b signalling is an important signalling pathway that regulates collagen expression and cardiac fibrosis. However, there was no difference of TGF-b signalling activation between OGN deficient and WT mice following Ang II infusion. It is reported that EGFR inhibitors attenuate cardiac hypertrophy induced by Ang II. 26 Consistent with this, we established that OGN deficient Interestingly, we observed that OGN suppresses the shedding of proHB-EGF and proamphiregulin by antagonizing extracellular MMP-2 activity. MMP-2 is a constitutively expressed gelatinase that is secreted as a latent form that requires activation by the membrane protease MT1-MMP. 31 Inhibition of MMP-2 activation retards CMF invasion and thus attenuates left ventricular remodelling and dysfunction. 32 These results suggest that OGN could suppress MT1-MMP membrane translocation and thus mediate CMF cytoskeleton remodeling.
Another interesting finding of this study is that that OGN directly binds to LPA3 to inhibit cardiac fibrosis by signalling through RhoA/ ROCK. LPA is an established activator of RhoA, which in turn activates the small GTP-binding protein Rho and induces rapid remodelling of the actin cytoskeleton via specific G-protein-coupled receptors (LPA1-6). 33 LPA receptors mediate a variety of cellular functions such as stimulation of cellular proliferation and migration, 34 platelet aggregation 35 and tumor cell invasion. In the cardiovascular system, elevated LPA levels have been observed in humans with ischemic heart disease. 36 LPA signalling also promotes pathological fibrosis in other conditions, such as renal and pulmonary fibrosis. 37, 38 We established LPA3 as the main participant that interacts with OGN. LPA3 is prominently expressed in the heart, pancreas and prostate, and to a lesser extent in the lung. 39 LPA also signals through LPA3 to induce proliferation and collagen synthesis in CMFs 40 and to facilitate the migration of epithelial ovarian cancer cells through G a13 /RhoA/ROCK dependent EGFR activation. 41 Administration of an LPA1/3 dual antagonist prevents radiation-induced lung fibrosis. 37 We found that treatment with LPA3 inhibitor Ki16425 attenuated cardiac interstitial fibrosis caused by OGN deficiency in vivo and inhibited proliferation and migration of OGN -/-CMFs in vitro, suggesting that LPA3 is an important factor in OGN mediated changes in CMF structure and function.
In summary, our current data establish a function of OGN in hypertension-related cardiac fibrosis. Disruption of OGN favours CMFs growth and facilitates cellular motility through LPA3/Rho/ROCKdependent MMP-2/EGFR/ERK signalling, contributing to extracellular matrix deposition and cardiac dysfunction.
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